Latest discoveries

China-developed COVID-19 vaccine to enter late-stage trial in Uzbekistan

Xinhua | Updated: 2020-11-14 19:18
A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd, in Beijing on March 16, 2020. [Photo/Xinhua]

TASHKENT -- The Uzbek government has recently told media that the country will carry out a phase-3 trial of a China-developed vaccine for COVID-19, which makes the vaccine China's fifth candidate to enter late-stage human tests overseas.

The ministry has announced that 5,000 Uzbek volunteers aged between 18 and 59 will attend the third phase of the pilot process, which will continue for a year.

Developed by China's Anhui Zhifei Longcom Biopharmaceutical, the trial vaccine has been transported to Uzbekistan along with several Chinese specialists who will work on the monitoring of participants and training of Uzbek doctors.

Uzbekistan has so far confirmed 69,830 COVID-19 cases and 594 deaths, with 67,092 patients recovered.

Please feel free to contact us by sending your questions to or commenting on China Daily app. We will ask experts to answer them.

Editor's picks
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349